Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Suk-Young | - |
dc.contributor.author | Choi, Yun Ji | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Kim, Jung Sun | - |
dc.contributor.author | Kang, Eun Joo | - |
dc.date.accessioned | 2021-09-01T01:20:32Z | - |
dc.date.available | 2021-09-01T01:20:32Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-11 | - |
dc.identifier.issn | 2072-1439 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/62043 | - |
dc.description.abstract | Background: The impacts of pulmonary function in patients with metastatic non-small cell lung cancer (NSCLC) and extended disease stage small cell lung cancer (SCLC-ED) treated with palliative chemotherapy remain to still be determined. Methods: Results of spirometry performed in 449 patients with either stage IV NSCLC (n=313) or SCLC-ED (n=136) at diagnosis were reviewed retrospectively. Overall survival (OS) was estimated using the Kaplan-Meier method and compared via a log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model. Results: The presence of chronic obstructive pulmonary disease (COPD) was not a risk factor for OS in either NSCLC or SCLC. However, NSCLC patients with COPD with a forced expiratory volume in one second (FEV1) value of less than 80% predicted were associated with a worse OS in both univariate and multivariate analyses [hazard ratio (HR): 1.43; 95% confidence interval (CI): 1.04-1.97; P=0.03]. Intriguingly, only the OS of NSCLC patients treated with chemotherapeutic agents was affected by the airflow limitation FEV1 value of less than 80% predicted (P=0.02). Patients with an FEV1 value of less than 80% predicted treated with targeted agents were not associated with OS (P=0.24). On the other hand, NSCLC patients with COPD were significantly linked to the occurrence of pulmonary complications during palliative therapy (P=0.01) but not associated with death resulting from pulmonary complications (P=0.22). Conclusions: Careful attention is required when chemotherapeutic agents are administered to patients with metastatic NSCLC with accompanying COPD with a FEV1 value of less than 80% predicted. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AME PUBL CO | - |
dc.subject | FORCED EXPIRATORY VOLUME | - |
dc.subject | ONE 2ND | - |
dc.subject | COPD | - |
dc.subject | SURVIVAL | - |
dc.subject | IMPACT | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | DOCETAXEL | - |
dc.subject | NIVOLUMAB | - |
dc.subject | EMPHYSEMA | - |
dc.subject | PREDICTS | - |
dc.title | Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Yun Ji | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.identifier.doi | 10.21037/jtd.2019.10.77 | - |
dc.identifier.scopusid | 2-s2.0-85077122155 | - |
dc.identifier.wosid | 000499662800032 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THORACIC DISEASE, v.11, no.11, pp.4562 - 4572 | - |
dc.relation.isPartOf | JOURNAL OF THORACIC DISEASE | - |
dc.citation.title | JOURNAL OF THORACIC DISEASE | - |
dc.citation.volume | 11 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 4562 | - |
dc.citation.endPage | 4572 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | FORCED EXPIRATORY VOLUME | - |
dc.subject.keywordPlus | ONE 2ND | - |
dc.subject.keywordPlus | COPD | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | EMPHYSEMA | - |
dc.subject.keywordPlus | PREDICTS | - |
dc.subject.keywordAuthor | Advanced lung cancer | - |
dc.subject.keywordAuthor | obstructive lung disease | - |
dc.subject.keywordAuthor | lung function | - |
dc.subject.keywordAuthor | prognostic indicator | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.